New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
15:25 EDTPVCT, PVCTProvectus Pharmaceuticals to host conference call
Conference Call to provide updates on the Phase 3 clinical trial of PV-10 will be held on June 19 at 4 pm. Webcast Link
News For PVCT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2015
10:28 EDTPVCTProvectus to host special shareholder meeting
Subscribe for More Information
06:13 EDTPVCTProvectus' intralesional RB decrease tumour burden in animal models
Provectus Biopharmaceuticals reported that the Journal of Clinical and Cellular Immunology has published a paper titled, "The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses." Authors state that their "article serves to evaluate the potential of intralesional rose bengal, or RB, to stimulate T-cell mediated anti-tumor responses in in-vitro, pre-clinical, and clinical studies." The review covers findings in both animal models and human clinical trials covering the use of intralesional RB in the treatment of: melanoma, breast cancer, ovarian cancer, gastric cancer and sarcoma. They conclude, "Our current research is establishing the role of RB in generating anti-tumor immune responses in gastrointestinal cancer and liver metastases. Decrease in tumor burden and stimulation of an immune response with PV-10 has been demonstrated in animal models of metastasis, and correlations of these responses in clinical studies is consistent with such results. That PV-10 treatment can potentially increase circulating cytotoxic T-cells, even in patients who were previously treated with immune-activating checkpoint blockade, supports the possibility that RB induced cytotoxicity may activate T-cells that are responsible for the bystander effect on untreated lesions. As such, intralesional therapy with RB may be a promising new mode of therapy to stimulate T-cell mediated anti-tumor immune responses."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use